Outcomes of magnetic sphincter augmentation - A community hospital perspective

- We report the early experience with MSA from two community-based health systems.
- GERD medications decreased from 98% preoperative to 8% postoperative (P<0.001).
- Median GERD-HRQL improved from 27 preoperative to 5 postoperative (P<0.001).
- Patient satisfaction increased from 8% preoperative to 84% postoperative (P<0.001).
- Results were similar to the trial data, indicating the reproducibility of MSA.

BackgroundMagnetic sphincter augmentation (MSA) is FDA approved for the surgical treatment of GERD. While multiple reports from academic settings exist, we report the early experience from two community-based health systems.MethodsThe first 102 post-trial cases of MSA were reviewed. Outcomes were compared to those in the initial clinical trial.ResultsMean follow-up duration was 7.6 months. GERD medication use decreased from 98% preoperative to 8% postoperative (P<0.001). Median GERD health-related quality of life (HRQL) improved from 27 preoperative to 5 postoperative (P<0.001). Patient satisfaction increased from 8% preoperative to 84% postoperative (P<0.001). Results were similar to the trial data.ConclusionsMSA is a safe and effective treatment for GERD, with significant improvement in quality of life. GERD-HRQL, medication reduction, operative times, and dysphagia rates were similar to other reports, demonstrating the reproducibility of MSA. Lower dilation rates may be due to refinements in technique and postoperative dietary management.